drugset
drugset / Trial / NCT05190744

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744 ↗

Phase 2 Completed 36 enrolled Mayo Clinic Otsuka America Pharmaceutical · collab
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or frequent urination related to inherited nephrogenic diabetes insipidus as an inherited condition or as an acquired condition from prior treatment with lithium.

Timeline

Start
2022-09-01
Primary completion
2025-12-08
Completion
2025-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Probenecid Small molecule 1000 mg —

Indications

autosomal dominant polycystic kidney disease nephrogenic diabetes insipidus